Cancer neurologists at Brigham and Women’s Hospital (BWH) are a critical part of a multidisciplinary team of specialists at the Center for Neuro-Oncology at the Dana-Farber/Brigham and Women’s Cancer Center (DFBWCC). Working together with neurosurgeons, radiation oncologists, medical oncologists,
psychiatrists, nurses and social workers, BWH neuro-oncologists are instrumental in providing world-class care for patients with tumors of the nervous system and neurologic complications of systemic cancer.
Led by Patrick Y. Wen, MD, Director, neurologists provide coordinated consultations, treatment and cutting-edge therapy for adult neuro-oncology patients. Our program provides diagnosis and treatment of neurologic complications of cancer and cancer therapies, and prevention of tumor growth and improved tumor response through chemotherapy and radiotherapy.
Meet the Cancer Neurology Team
Cancer Neurology Physicians
Conditions We Treat
Specialists evaluate and treat adult patients with a variety of disorders, including:
To Schedule an Appointment, Contact:
Dana-Farber/Brigham and Women’s Cancer Center
Department of Neurology/Division of Cancer Neurology
44 Binney Street
Boston, MA 02115
Phone: (617) 632-2166
Fax: (617) 632-4773
For Medical Professionals
The BWH Neuro-Oncology program sponsors ACGME-accredited fellowship training.
The first year of the fellowship is devoted to an intensive exposure to clinical neuro-oncology. Each trainee gains extensive experience in the full spectrum of diseases and problems encountered in neuro-oncology. There is comprehensive training and experience in the administration of chemotherapy and management of chemotherapy complications. The first-year fellows rotate between the neuro-oncology services at Brigham and Women’s Hospital, Dana Farber Cancer Institute (DFCI) and Massachusetts General Hospital.
The rotation at BWH/DFCI includes management of patients in the neuro-oncology service and neuro-oncology consultations requested by other services (oncology, medicine, neurology, neurosurgery). Fellows work closely each month with the attending neuro-oncologists, nurses and nurse practitioners in the inpatient setting at BWH. Patients are usually admitted to the “DMD” Dawson Neurology Service and are managed in collaboration with neurology residents and Harvard Medical School students. The rotation at DFCI also includes attending several neuro-oncology staff clinics each week. Fellows also receive formal mentoring for clinical research projects.
The Neuro-Oncology Training Program at BWH/DFCI welcomes applications from graduates of training programs in neurology, hematology/oncology, pediatric oncology, neurosurgery and radiation oncology. Trainees are accepted each year, with clinical rotations starting in July.
Interested candidates can contact the Brigham and Women’s Hospital Neuro-Oncology Service at:
Department of Neurology
Division of Cancer Neurology
Brigham and Women’s Hospital/Dana Farber Cancer Institute
Attn. Vida Tafoya, Administrative Assistant
44 Binney Street SW 430
Boston, MA 02115
Phone: 617-632-6158
Vida_Tafoya@dfci.harvard.edu
Additional information regarding requirements and the application process for the joint fellowship program can be found here:
http://brain.mgh.harvard.edu/btc_fellowship.htm
Publications
Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1;15(1):330-7.
Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008 Dec;7(12):1152-60.
Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2008 Nov 29.
Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 2008 Aug 5.
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008 Jul 31;359(5):492-507.
Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7.
Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87.
Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007 Nov;25(4):1035-71.
Send Feedback to: 
